Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1226656 | 0.83 | CA12 (0.35) | CA12CA1CA2CA9CYP3A4 | |
| SCHEMBL1225829 | 0.78 | — | — | |
| SCHEMBL17059042 | 0.76 | CA12 (0.39) | CA12CA1CA2CA9CYP3A4 | |
| SCHEMBL1226329 | 0.74 | CA12 (0.41) | CA12CA1CA2CA9CYP3A4 | |
| SCHEMBL3343087 | 0.74 | CA12 (0.38) | CA12CA1CA2CA9CYP3A4 | |
| SCHEMBL1225380 | 0.73 | CA12 (0.49) | CA12CA1CA2CA9CYP3A4 | |
| SCHEMBL30745145 | 0.72 | MGLL (0.44) | CA12CA1CA2CA9 | |
| SCHEMBL3343084 | 0.70 | MKNK1 (0.39) | CA12CA1CA2CA9CYP3A4 | |
| SCHEMBL31514120 | 0.70 | CA12 (0.36) | CA12CA1CA2CA9CYP3A4 | |
| SCHEMBL31514103 | 0.69 | CA12 (0.38) | CA12CA1CA2CA9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8435990-B2 | Dihydropyrimidone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2459541-A1 | DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-06-06 | — | — | EP | disclosed |
| CN-102471284-A | Dihydropyrimidone amides as P2X7 modulators | HOFFMANN LA ROCHE | 2012-05-23 | — | — | CN | disclosed |
| US-20110028502-A1 | DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS | BROTHERTON-PLEISS CHRISTINE E | 2011-02-03 | — | — | US | disclosed |
| WO-2011012592-A1 | DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028502-A1 | DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS | P2RY1, P2RX7, P2RX3 | CA12 4774/4885CA1 3391/4885CA2 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.